Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-014078
Filing Date
2025-04-16
Accepted
2025-04-16 08:02:20
Documents
18
Period of Report
2025-05-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20044394x1_def14a.htm   iXBRL DEF 14A 742189
6 ny20044394x1-pc_1.jpg GRAPHIC 587878
7 ny20044394x1-pc_2.jpg GRAPHIC 615739
8 sig_timran.jpg GRAPHIC 25012
  Complete submission text file 0001140361-25-014078.txt   4339597

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA rani-20250528.xsd EX-101.SCH 3431
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE rani-20250528_def.xml EX-101.DEF 3076
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE rani-20250528_lab.xml EX-101.LAB 3365
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE rani-20250528_pre.xml EX-101.PRE 6800
20 EXTRACTED XBRL INSTANCE DOCUMENT ny20044394x1_def14a_htm.xml XML 58031
Mailing Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131
Business Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700
Rani Therapeutics Holdings, Inc. (Filer) CIK: 0001856725 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40672 | Film No.: 25841261
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)